UK Markets closed

GH Dec 2022 200.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.57000.0000 (0.00%)
As of 09:50AM EST. Market open.
Full screen
Previous close3.5700
Open3.5700
Bid0.5000
Ask2.6500
Strike200.00
Expiry date2022-12-16
Day's range3.5700 - 4.0600
Contract rangeN/A
Volume3
Open interest29
  • Business Wire

    Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

    REDWOOD CITY, Calif., January 18, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80. The study is anticipated to run in approximately 100 centers

  • Motley Fool

    Why Guardant Health Fell More Than 5% Today

    The healthcare company can't provide a clear picture of where it is with respect to the COVID-19 pandemic.

  • Business Wire

    Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation

    REDWOOD CITY, Calif., January 07, 2022--Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Guardant Health $25 million as well as future royalties for the remaining term of the licensed digital sequencing technology patents. In turn, Guardant Health will grant Foundation M